Study of Acceleration Therapeutics' AT-101 Reveals for the First Time That Nitric Oxide is Released Into the Human Bloodstream NORTH BAY VILLAGE, Fla.–(BUSINESS WIRE)–Dec. 7, 2004-
-Acceleration Therapeutics Division of Non-Invasive Monitoring Systems, Inc. (NIMS) (OTCBB:NIMU) announces that Drs. Kuchera and Daghigh of the Philadelphia College of Osteopathic Medicine demonstrated that non-invasive treatment with the AT-101 motion platform elevates serum nitrite in humans. These results were presented at the annual meeting of the American Osteopathic Association on November 7-11 in San Francisco. Dr. Kuchera stated, "Nitrite serves as a marker for release of nitric oxide into the circulation since nitric oxide itself is metabolized within a few seconds. Our assay reliably measures small elevations of nitrite caused by AT-101 activation of an enzyme present within the inner lining of blood vessels responsible for nitric oxide production. This action of the AT-101 is important since nitric oxide generated with this enzyme has vasodilator, anti-arteriosclerotic, anti-inflammatory and neurotransmittor properties." Dr. Kuchera added, "Subjects included normals and patients with diabetes, Fibromyalgia, multiple sclerosis and other inflammatory disorders.
Most patients reported improvements in their physical and medical status after AT-101 treatments independent of changes in nitrite. Increase of nitrite was not as consistent or as significant in patients compared to normals. This difference might relate to dysfunction of the protein in the inner lining of blood vessels and will require further research." The AT-101 is a comfortable platform, mounted on a hospital-like gurney, that moves the body repetitively in a back and forth motion from head to foot. It is currently listed with the FDA as a Class I (exempt) powered exercise device intended as an aid to improve the circulation and joint mobility. Medicare and insurance companies under CPT 97710, Therapeutic Exercises, reimburse its application in most chronic neurological and rheumatologic diseases as well as acute soft tissue and bone injuries.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. Contacts: Non-Invasive Monitoring Systems, Inc., North Bay Village Deborah Goldring, 305/861-0075. firstname.lastname@example.org